Stamford, CT-based Sema4, a genomics company spun out of Mount Sinai Health System, completed its merger with special purpose acquisition company CM Life Sciences today.
Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, will begin trading on the Nasdaq under SMFR tomorrow.
The transaction values Sema4 at an enterprise value of approximately $2 billion.
Announced in February, the deal is expected to provide aproximately $500 million in cash proceeds to shareholders and Sema4. Read more.
